Abstract
The number of patients with type 2 diabetes is increasing worldwide and the same is true also in Czech Republic. Despite many new antidiabetic treatments emerging, still more than half of patients is not optimally controlled and the risk of developing long-term complications is increased.
Fixed dose combinations of different drugs help to improve treatment compliance and therefore help to reach better treatment results. New fixed dose combination empagliflozin/linagliptin combines two oral antidiabetic drugs with complementary effects - empagliflozin (inhibitor of renal glucose transporter SGLT2) and linagliptin (DPP4 inhibitor).
This fixed dose combination has proven clinical efficacy and safety and because of the presence of empagliflozin and its proven cardiovascular benefit it is now the only fixed dose combination antidiabetic drug in which we can expect effects beyond glycaemic control in patients with type 2 diabetes - especially the reduction of cardiovascular and all-cause mortality.